Background Mepolizumab, an anti-interleukin-5 monoclonal antibody approved as add-on
therapy to standard of care for patients with severe eosinophilic asthma, has been shown in …

Background Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic
phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed …

Background As asthma symptoms worsen, patients typically rely on short-acting β 2 -agonist
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …

Background Mepolizumab has demonstrated favorable safety and efficacy profiles in
placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. …

Renal artery stenosis (RAS) is a relatively uncommon but important potentially reversible
cause of renal failure. Little is known about the natural history of ischemic renal disease …

Background Asthma exacerbations are frequent in patients with severe disease. This report
describes results from two retrospective cohort studies describing exacerbation frequency …

The last decade has seen the approval of several new biologics for the treatment of severe
asthma-targeting specific endotypes and phenotypes. This review will examine how evidence …

Background Many patients with severe asthma require maintenance treatment with systemic
corticosteroids (SCSs) to control daily symptoms and prevent serious acute exacerbations, …

Background Three anti–IL-5 pathway–directed therapies are approved for use in patients
with severe eosinophilic asthma (SEA); however, no head-to-head comparison data are …

Sensitivities of cirrus cloud radiative forcing as well as solar albedo and infrared emittances
to ice crystal size spectrum and ice crystal shape were examined using a coupled cloud-…